Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Last Updated: Tuesday, November 30, 2021
Data from a recent retrospective study of 289 patients with polycythemia vera demonstrated no significant difference between the number of patients with ruxolitinib-associated secondary malignancies (n = 10; 41.7%) and patients (n = 14; 58.3%) who developed secondary malignancies without receiving ruxolitinib (P = 0.34, chi square test).
Advertisement
News & Literature Highlights
